Midlife Empowerment and Longevity Through Optimizing Wellness
MELOW
Enhancing Healthy Longevity in At-Risk Midlife Women With Abdominal Obesity: A Digital Phenotyping Commitment Device on Improving Visceral Body Fat Mass, Menopausal Symptoms and Cardiometabolic Risk Factors
1 other identifier
interventional
200
0 countries
N/A
Brief Summary
The goal of this observational longitudinal study is to understand how lifestyle behaviours, menopausal symptoms, and digital health data change over time in women experiencing perimenopause or menopause, and to evaluate whether a personalised digital health programme can support healthier lifestyle behaviours and improve cardiometabolic health. The main questions it aims to answer are:
- 1.Can personalised lifestyle recommendations informed by wearable devices, dietary logging, and self-reported symptoms improve adherence to healthy diet, physical activity, and sleep behaviours?
- 2.How are menopausal symptoms associated with changes in cardiometabolic health, body composition, physical function, and quality of life over time?
- 3.Attend study visits at the National University of Singapore for health assessments, including measurements of body composition, physical function, and cardiometabolic health.
- 4.Wear a smartwatch or wearable device to monitor physiological and activity data throughout the study.
- 5.Use a mobile application to record dietary intake, menopausal symptoms, and other health-related information.
- 6.Receive personalised lifestyle recommendations based on their health data and engage in regular follow-up assessments over the study period.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jan 2027
Typical duration for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 15, 2026
CompletedFirst Posted
Study publicly available on registry
July 20, 2026
CompletedStudy Start
First participant enrolled
January 1, 2027
ExpectedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2029
Study Completion
Last participant's last visit for all outcomes
January 1, 2030
July 23, 2026
July 1, 2026
2 years
July 15, 2026
July 22, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Change in Menopause Rating Scale (MRS)
Menopause Rating Scale (MRS) is an 11-item questionnaire used to measure the severity of menopausal symptoms and the impact on quality of life. It evaluates 11 symptoms on a 0 to 4 scale, whereby 0 is 'No symptoms', 1 is 'Mild' 2 is 'Moderate', 3 is 'Severe', and 4 is 'Extremely severe'. The MRS score with a minimum score of 0 and maximum score of 44. The higher the score, the more severe the menopause symptoms.
Change in Menopause Rating Scale (MRS) score from enrolment to 6 month mark
Study Arms (2)
Control
NO INTERVENTIONParticipants in the control group will not have access to the MELOW app during the study period
MELOW
EXPERIMENTALParticipants will be required to download and set up an app on your smartphone and complete a short health goal-setting exercise. They will be asked to respond to brief check-in questions through the app at least three times a day regarding energy levels, mood, appetite, and any symptoms such as hot flushes or sleep difficulties. Participant will then receive short personalised messages through the app based on wearables data and responses to support in managing symptoms and maintaining healthy habits. The app will send reminders if it receives no response to the prompts. They will also be able to view a personalised health dashboard on the app, updated regularly as device data syncs.
Interventions
Participants will be required to download and set up an app on your smartphone and complete a short health goal-setting exercise. They will be asked to respond to brief check-in questions through the app at least three times a day regarding energy levels, mood, appetite, and any symptoms such as hot flushes or sleep difficulties. Participant will then receive short personalised messages through the app based on wearables data and responses to support in managing symptoms and maintaining healthy habits. The app will send reminders if it receives no response to the prompts. They will also be able to view a personalised health dashboard on the app, updated regularly as device data syncs.
Eligibility Criteria
You may qualify if:
- Women aged 21-65 years old;
- Report at least mild climacteric symptoms as indicated by an MRS score ≥5;
- Waist circumference ≥80 cm, indicating abdominal adiposity;
- Own and use a smartphone compatible with the CGM and Oura Ring.
You may not qualify if:
- Are currently receiving hormone replacement therapy (HRT);
- Are currently using oral contraceptives;
- Have been diagnosed with severe psychiatric illness requiring inpatient care;
- Are concurrently enrolled in another behavioural or psychotherapy trial;
- Have significant cognitive impairment or inability to engage with digital tools;
- Have uncontrolled chronic medical conditions that may interfere with study participation;
- Unable to comprehend written and spoken English.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor, Alice Lee Centre for Nursing Studies, Yong Loo Lin School of Medicine, National University of Singapore (NUS)
Study Record Dates
First Submitted
July 15, 2026
First Posted
July 20, 2026
Study Start (Estimated)
January 1, 2027
Primary Completion (Estimated)
January 1, 2029
Study Completion (Estimated)
January 1, 2030
Last Updated
July 23, 2026
Record last verified: 2026-07